Eye­ing a big heart fail­ure mar­ket, scPhar­ma­ceu­ti­cals aims for $100M IPO

Af­ter lin­ing up an ap­pli­ca­tion for FDA ap­proval of a new ap­proach to treat­ing flu­id re­ten­tion in heart fail­ure pa­tients a few months ago, Burling­ton, MA-based scPhar­ma­ceu­ti­cals is shoot­ing for a $100 mil­lion IPO.

The biotech has de­vel­oped a new for­mu­la­tion of furosemide so it could be de­liv­ered via a wear­able de­vice, rather than de­liv­ered through an IV in the hos­pi­tal. The com­bo has the sim­ple in­ten­tion of re­duc­ing the num­ber of days a pa­tient has to be hos­pi­tal­ized for ther­a­py — in a heart fail­ure mar­ket that ac­counts for mil­lions of pa­tients — and the biotech has plans for more IV-re­place­ment pro­grams much like it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.